Liability to substance use disorders: 1. Common mechanisms and manifestations

被引:155
|
作者
Vanyukov, MM
Tarter, RE
Kirisci, L
Kirillova, GP
Maher, BS
Clark, DB
机构
[1] Univ Pittsburgh, Dept Pharmaceut Sci, CEDAR, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Dept Psychiat, CEDAR, Pittsburgh, PA 15261 USA
[3] Univ Pittsburgh, Dept Human Genet, CEDAR, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Sch Dent Med, CEDAR, Ctr Dent & Craniofacial Genet,Div Oral Biol, Pittsburgh, PA 15261 USA
来源
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS | 2003年 / 27卷 / 06期
关键词
addiction; drug abuse; vulnerability; susceptibility; etiology; complex traits; phenotype; DEFICIT HYPERACTIVITY DISORDER; CROSS-FOSTERING ANALYSIS; FAMILIAL TRANSMISSION; ENVIRONMENTAL-INFLUENCES; DOPAMINE TRANSMISSION; ANTISOCIAL-BEHAVIOR; GENETIC-ANALYSIS; ALCOHOL-PROBLEMS; NOVELTY SEEKING; DRD5; GENE;
D O I
10.1016/j.neubiorev.2003.08.002
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Variation in the risk for and severity of substance use disorders (SUD) in the population is caused by multiple organismic (genetic, biochemical, psychological) and environmental factors. Whereas drug- or drug-class-specific liability mechanisms exist, a substantial proportion of variance in the risk is shared between specific liabilities, reflecting mechanisms that determine common liability to SUD. Data from epidemiologic, clinical, psychological, physiological, biochemical, and family and genetic studies reviewed in this paper indicate the existence of mechanisms and characteristics shared in common by liabilities to SUD related to different drugs. These mechanisms can be conceptualized as common. liability to SUD, a latent trait accounting for a substantial portion of variation in SUD risk and severity and determined by all factors influencing the probability of SUD development. An accompanying paper describes an approach to the quantitative estimation of this trait. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:507 / 515
页数:9
相关论文
共 50 条
  • [31] An overview of commonalities in the mechanisms underlying gambling and substance use disorders
    Singer, Bryan F.
    Anselme, Patrick
    Robinson, Mike J. F.
    Vezina, Paul
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2020, 101
  • [32] Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders
    Ferre, Sergi
    PSYCHOPHARMACOLOGY, 2016, 233 (10) : 1963 - 1979
  • [33] Substance Use Disorders Refresh: Nonopioid Substance Use Disorders
    Zhao, Nan
    Jorgensen, Shea
    Dixon, Lisa B.
    PSYCHIATRIC SERVICES, 2023, 74 (09) : 1006 - 1007
  • [34] Translational Research in the Neurobiological Mechanisms of Alcohol and Substance Use Disorders
    Carolina L. Haass-Koffler
    Jesse R. Schank
    Neurotherapeutics, 2020, 17 : 1 - 3
  • [35] Substance Use Disorders and Addiction: Mechanisms, Trends, and Treatment Implications
    Kalin, Ned H.
    AMERICAN JOURNAL OF PSYCHIATRY, 2020, 177 (11): : 1015 - 1018
  • [36] ADHD and comorbid substance use disorders: mechanisms and clinical implications
    Schellekens, A.
    EUROPEAN PSYCHIATRY, 2019, 56 : S656 - S656
  • [37] Genome-wide molecular mechanisms of substance use disorders
    Blokhin, Ilya O.
    Martinez-Garza, David M.
    Patel, Dhruti
    Douaihy, Antoine B.
    Salloum, Ihsan M.
    FRONTIERS IN PSYCHIATRY, 2024, 14
  • [38] Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders
    Sergi Ferré
    Psychopharmacology, 2016, 233 : 1963 - 1979
  • [39] Substance use disorders and schizophrenia: a question of shared glutamatergic mechanisms
    Coyle, Joseph T.
    NEUROTOXICITY RESEARCH, 2006, 10 (3-4) : 221 - 233
  • [40] Substance use disorders: Psychoneuroimmunological mechanisms and new targets for therapy
    Loftis, Jennifer M.
    Huckans, Marilyn
    PHARMACOLOGY & THERAPEUTICS, 2013, 139 (02) : 289 - 300